StockWatch
·

Bharat Parenterals Ltd Q2 FY27 Results

BPLPHARMAQ2 FY27 Results
Filing
Result:Good· Market: Up#Turnaround#Margin expansion#Base effect

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue136.2845.4%110.9%
Total Income138.8246.4%103.7%
Expenditure124.8329.6%65.4%
PBT14.001037.4%291.2%
Net Profit11.82431.7%237.3%
OPM17.30%8.20pp16.03pp
NPM8.51%12.27pp21.14pp
EPS17.15231.7%22.5%
View full financials

Pharma manufacturer swung from a loss to ₹11.8 Cr profit with OPM expanding from 1.3% to 17.3% on 111% revenue growth, but the jump is off a depressed/small prior-year base, capping it below very_good.

BHARAT PARENTERALS · Q2 FY27 · THE VERDICT

Innoxel Inflection, Margin Test — The Real Quarter Below the Headline

Consolidated revenue soared 110%, PAT swung to profit, and the first CMO export shipped in October. But management maintained guidance, not raised it. The call explains why—material costs have compressed margins below band, and CMO commercial proof is still pending.

02 Nov 2026 · 6 min read
Reported Revenue

₹136.3 Cr

+110% YoY

Reported PAT

₹11.8 Cr

vs loss ₹6.6 Cr prior year; +237% YoY

Innoxel H1 revenue

₹65.9 Cr

+219% YoY; 91% of full FY26

Standalone Q2 margin

9% EBITDA

vs 10-15% guided; below band

The quarter headlines as a breakout: consolidated revenue up 110%, PAT swinging from a loss ₹6.6 crore to profit ₹11.8 crore. But the call reveals a more textured story. Innoxel is showing the structural inflection management promised—first CMO export live in October, H1 revenue ₹65.9 crore matching 91% of the entire prior fiscal year—but standalone BPL is grappling with material cost inflation that has compressed margins below guidance. Management kept FY27 guidance unchanged, not raised it. That gap, between the headline momentum and the cautious tone, is the quarter's real signal.

Where the profit really came from

Innoxel is carrying the inflection. Its EBITDA surged to ₹14.6 crore in Q2 (versus a loss of ₹2.1 crore a year ago), lifting consolidated profit to ₹11.8 crore. But this isn't a steady-state margin: Q2's 33% EBITDA margin at Innoxel was inflated by licensing milestone income, which management made clear is lumpy and non-recurring. The H1 reality is starker—Innoxel EBITDA margin sits 'just under the 20% floor' of the 20-25% guidance band, even as revenue towers 219% higher. Meanwhile, standalone BPL's EBITDA margin fell to 9% in Q2 (versus 10-15% guided), squeezed by material cost inflation that management quantified at 5 percentage points of revenue in a single quarter. Gross margin collapsed 9 percentage points year-on-year to 35%. Until this cost pressure eases or passes through to customer pricing, margin guidance sits at risk—and management's silence on FY28-FY29 targets suggests they don't expect near-term recovery.

Management's claims vs. what holds up

Innoxel H1 revenue up 219%, nearly matching full FY26

Supported

H1 ₹65.9 Cr is 91% of FY26 ₹72.4 Cr; growth 219% confirmed

Innoxel margin 33% in Q2 shows path to 20-25% guidance

Mixed

Q2 is 33% but weighted by licensing milestones (non-recurring); H1 'just under 20%' is the real profile. Recurring CMO supply margin unproven.

Standalone H1 revenue broadly flat YoY

Overstated

H1 ₹134.1 Cr vs prior ₹136.1 Cr = down 1.5%; Q1 weak (exports deferred), Q2 strong (+88% YoY). Not flat.

Standalone EBITDA margin inside 10-15% guidance band

Contradicted

H1 10.3% (inside band) but Q2 only 9% (below band); material costs up 5% of revenue

What changed on this call

Innoxel CMO has crossed from R&D to revenue. The first product under the CMO partnership exported to the US on October 20—a commercial milestone that shifts Innoxel from licensing/development into recurring supply. Management now guides for CMO sales to scale alongside licensing deals and milestone income. Standalone BPL's order book recovered to ₹117 crore (from ₹65 crore in September), but much of that was one-time: ₹30 crore from a deferred export tender executed in Q2 alone. The real test is new registrations and EU GMP approvals; management could not specify a timeline for either, saying the GMP inspection will conclude 'sometime during FY27.' Varenyam Healthcare grew H1 revenue 43% (well ahead of its 20-25% FY27 guidance), yet management held guidance firm—the new oncology division launch is a cost drag through Q3 or Q4. Varenyam Bio spent ₹33.7 crore of its ₹300 crore Phase 1 capex in Q2, targeting completion by Q2 CY28; management deferred Phase 2 scope and capex sizing to later, pending contract closure.

The bull-bear ledger
  • Innoxel CMO inflection structural: first export live (Oct 20), 4 validated lines, ₹45 Cr order book from supply alone

  • H1 revenue trajectory (₹65.9 Cr in 6 months, 219% growth) suggests exit-rate annualized run-rate >₹130 Cr

  • Consolidated PAT swung from loss ₹6.6 Cr to profit ₹11.8 Cr; Innoxel EBITDA ₹14.6 Cr (vs loss ₹2.1 Cr prior year)

  • Standalone order book ₹117 Cr and capacity headroom (70% utilization vs 48.5% FY26) provide H2 growth runway

  • Varenyam Healthcare ahead of guidance pace (43% H1 growth); new oncology division will drive next phase

  • Material cost inflation real: gross margin down 9pp YoY; Innoxel H1 margin 'just under 20%' (not 20-25%)

  • Standalone H1 flat YoY (₹134.1 Cr vs ₹136.1 Cr); Q2 strength masks Q1 weakness; growth dependent on new registrations & approvals

  • Innoxel Q2 margin 33% inflated by licensing income; recurring CMO supply margin unproven; licensing is tail-down over time

  • Varenyam Bio: ₹300 Cr capex pre-revenue, with no signed innovator deals disclosed; Phase 2 scope undefined

  • CMO commercial ramp unproven: partner 'waiting for binding forecast' from first export order; no firm FY28 ramp guidance given

  • Management maintained all FY27 guidance (not raised) despite strong Innoxel growth—signals caution on cost recovery or CMO ramp speed

Risks, ranked by how much they should concern a holder

Material cost inflation persists; EBITDA at band edge

High

Gross margin at 35% (down 9pp YoY); Q2 standalone EBITDA only 9% vs 10-15% guidance. If costs remain elevated through H2 or into FY28, margin guidance could miss despite revenue beat. Pricing power in tender segment unclear.

Innoxel CMO commercial ramp slower than momentum suggests

High

First order exported Oct 20, but binding forecast from partner not yet received. H1 margin 'just under 20%' (not 20-25% guided). Recurring CMO supply volume, pricing, and margin trajectory unproven. Slower ramp would cap FY28 targets.

Standalone H1 flat YoY; organic growth depends on new registrations

Medium

Q1 weak (export shipments deferred), Q2 strong (backlog catch-up). ₹117 Cr order book is mostly tail-down supply. Future growth needs EU GMP approval (timeline TBD), new dossier filings, and new product registrations. Execution risk if approvals slip.

Varenyam Bio ₹300 Cr capex pre-revenue; no signed innovator deals

Medium

Phase 1 on track (₹33.7 Cr spent Q2, target completion Q2 CY28). But pre-revenue capex without binding demand is speculative. Phase 2 scope undefined. Path to profitability depends on unproven innovator deal flow; no term sheet disclosed.

Innoxel licensing revenue lumpy; recurring CMO margin unclear

Low-Medium

Management stated 'most revenue from milestones and licensing.' Q2 33% margin is not representative; H1 'just under 20%' is the real profile for recurring supply. As licensing tails down over time, CMO supply margin becomes the gate. Contract structure & pricing for CMO profit-share unproven.

The market has cooled on the stock since its all-time high of ₹2,292.15, with the share priced at ₹2,026.65 today—an 11.6% drawdown. Yet it sits 130% above its 52-week low and is trading above all key moving averages (SMA20 ₹1,839.4, SMA50 ₹1,677.65, SMA200 ₹1,338.24), signaling confidence in the long-term thesis. The problem: institutional participation is muted. FII ownership is frozen at 0.11% (no buying momentum), DII at 1.37% in Q1 FY27 (marginal), and the promoter's 67.2% stake is stable. The stock's tepid institutional response to a structural inflection (CMO live, Innoxel revenue +219%) suggests the market is waiting for two things: (1) evidence that material cost inflation will ease, and (2) proof that CMO commercial ramp can accelerate without sacrificing margin. The pullback from ATH combined with rising volume but flat FII/DII ownership hints that the near-term narrative is unresolved.

What to watch next
  • 1 · Q3 Innoxel CMO commercial ramp (Oct–Dec 2026)

    Partner's binding forecast from the Oct 20 export order. Recurring CMO supply revenue, volume, and EBITDA margin (ex-licensing). Rate of new deal closure (6 signed in H1; management guided 10-12 expected by Q3 end). This is the proof point for the inflection.

  • 2 · Standalone H2 organic growth and approvals (Jan–Mar 2027)

    New product registrations, EU GMP approval outcome (inspection ongoing; management says 'sometime FY27' but no timeline). Q3-Q4 order book replenishment (vs. tail-down of ₹117 Cr). Confirm momentum is organic growth, not backlog catch-up. Pricing recovery for new orders (management claimed prices rising, but existing book already priced).

  • 3 · FY28 guidance reset (Feb 2027)

    Innoxel revenue and EBITDA margin targets for FY28. Varenyam Healthcare and Varenyam Bio guidance (capex, profitability path). Implicit material cost inflation assumption and CMO commercial ramp assumptions. FY29 commentary on Innoxel scale and margin profile at ₹200-300 crore revenue (management guided 50-65% EBITDA long-term; H1 'just under 20%' suggests wide margin of execution risk).

Bharat Parenterals has a genuine structural inflection in Innoxel. First CMO export live. H1 revenue trajectory at 219% growth. Multi-year TAM visibility in specialty generics. But Q2 also shows that near-term execution is bumpy. Material cost inflation has compressed margins below guidance. The CMO ramp is real but early—binding forecast still awaited from the partner. Standalone BPL is growing, but from a platform that requires new EU approvals and product registrations to sustain organic growth.

Management's decision to maintain FY27 guidance rather than raise it, despite Innoxel's momentum, is the quarter's real tell. They are not confident that the inflection will flow through to bottom-line without margin recovery or accelerated CMO commercial traction. Varenyam Bio is strategically sound but years away from material contribution.

For a holder, the next gate is Q3: does the CMO partner confirm a binding forecast? Do margins stabilize? The single metric to track is Innoxel recurring EBITDA margin, stripping out licensing milestones. Until it breaks above 20% and holds, the inflection remains a promise, not a lock. This is a multi-year thesis; the near-term debate is unresolved.

Informational and educational content only. Not investment advice.